Yann-Alexandre Vano, MD

home / authors / yann-alexandre-vano-md

Articles

Vano Highlights Trials and Data in RCC

October 4th 2023

Yann-Alexandre Vano, MD, discusses some of the exciting data being seen in the renal cell carcinoma space.

Comparing BIONIKK Data of Nivolumab With/Without Ipilimumab in mRCC

Yann-Alexandre Vano, MD

May 3rd 2023

Yann-Alexandre Vano, MD, explains some of the findings from the phase 2 BIONIKK trial which evaluated nivolumab and ipilimumab in metastatic renal cell carcinoma.

The Impact of Biomarker-Driven Frontline Treatment in mRCC

Yann-Alexandre Vano, MD

April 11th 2023

Looking at the results of the BIONIKK trial, Yann-Alexandre Vano, MD, discusses the importance of having biomarkers drive treatment decisions in patients with metastatic renal cell carcinoma.

Updated Data From the Phase 2 BIONIKK Trial in RCC

Yann-Alexandre Vano, MD

February 17th 2023

Yann-Alexandre Vano, MD, discusses the main findings from the phase 2 BIONIKK trial that were presented at the 2023 Genitourinary Cancers Symposium.